Biomatters takes advantage of biological drug market
Local software developer says it can help pharmaceutical companies make drugs to target cancer.
Hot Topic
Hawke’s Bay
Auckland-based software developer Biomatters has designed an antibody analysis platform, which it says could help pharmaceutical companies make drugs to target diseases such as cancer.
The 13-year-old company, which already has a genetic code data analysis tool called Geneious used by about 3000
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Calida Smylie
Mon, 30 Jan 2017
Mon, 30 Jan 2017
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Biomatters takes advantage of biological drug market
64461